Navigation Links
Mylan Launches Generic Version of Cyklokapron® Injection
Date:12/2/2011

PITTSBURGH, Dec. 2, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tranexamic Acid Injection, 100 mg/mL, packaged in 1,000 mg/10 mL Single-dose Vials. This product is the generic version of Pharmacia & Upjohn's Cyklokapron® Injection, which is indicated for short-term use in patients with hemophilia to reduce or prevent hemorrhage during and following oral surgery.

Tranexamic Acid Injection had U.S. sales of approximately $17 million for the 12 months ending Sept. 30, 2011, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 165 ANDAs pending FDA approval representing $99.4 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
2. Mylan Launches Generic Version of Caduet® Tablets
3. Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
4. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
5. Mylan Receives Approval for Generic Version of Zinecard® for Injection
6. Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot®
7. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
8. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
9. Mylan to Acquire Pfizer Respiratory Delivery Platform
10. Mylan Receives Approval for Generic Version of MS Contin® Tablets
11. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Medtec Europe will once ... 600 exhibitors from 70 countries the opportunity to ... will advance the medical technology industry. Taking place ... Stuttgart, Stuttgart, Germany , Medtec ... the key trends and insights across the entire ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
(Date:3/27/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD is pleased to announce it has received conditional ... the TSX Venture Exchange.  Receiving the ... of significant achievements for Invictus-MD. Some of which include: ... AB Laboratories Inc. ("AB Labs"), a Licensed Producer under ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, the ... on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a business and ... April edition of American Veterinarian™. , “We look forward to launching ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... ... 27, 2017 , ... According to the American Cancer Society , the ... than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, ... to avoid this latter group, tune in to Lifestyle Magazine on April ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy ... resolve the pending litigation between itself and 1800 Vending DBA Healthy You Vending. ... “I am thrilled to announce that we have now reached a settlement agreement ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading ... bringing its latest products to the Deaf Seniors of America Conference, April 4-7 at ... to meet with knowledgeable ASL friendly staff from Harris Communications and to try out ...
Breaking Medicine News(10 mins):